论文部分内容阅读
目的:分析普米克令舒和可必特雾化吸入治疗哮喘性支气管炎的临床效果。方法:选取汕头大学医学院第二附属医院2014年5月至2015年6月收治的50例哮喘性支气管炎患者,随机分为观察组及对照组各25例。观察组给予普米克令舒和可必特雾化吸入治疗,对照组患者仅采用普米克令舒雾化吸入治疗。疗程均为2个月,观察并对比两组患者的临床有效性。结果:观察组的治疗总有效率95%显著高于对照组68%(P<0.05)。对照组的不良反应发生率60%高于观察组32%,差异具有统计学意义(P<0.05)。观察组的临床症状好转时间显著短于对照组(P<0.05)。结论:普米克令舒和可必特雾化吸入治疗哮喘性支气管炎,具有见效快、治疗效果好、不良反应少的特点。
OBJECTIVE: To analyze the clinical effect of pulmicort respules and nifibrate inhalation in the treatment of asthmatic bronchitis. Methods Fifty patients with asthma bronchitis admitted from May 2014 to June 2015 in the Second Affiliated Hospital of Shantou University Medical College were randomly divided into observation group and control group with 25 cases each. Patients in the observation group were treated with inhalation of pulmicort and canine, while those in the control group were treated with pulmicort respiration inhalation only. The course of treatment was 2 months. The clinical efficacy of the two groups was observed and compared. Results: The total effective rate of observation group was 95% higher than that of control group (P <0.05). The incidence of adverse reactions in the control group was 60% higher than that in the observation group (32%), the difference was statistically significant (P <0.05). The improvement of clinical symptoms in observation group was significantly shorter than that in control group (P <0.05). Conclusion: Pulmicort respules and Kebite inhalation are effective in treating asthmatic bronchitis. It has the characteristics of quick response, good curative effect and few adverse reactions.